Neuroone Medical Technologies (NasdaqCM:NMTC) Q1 2026 Earnings call February 17, 2026 08:30 AM ET Company ParticipantsDave Rosa - CEORon McClurg - CFOConference Call ParticipantsJeffrey Cohen - AnalystJeremy Pearlman - SVP and Equity Research AnalystOperatorGood day, ladies and gentlemen, and welcome to the first quarter fiscal 2026 financial results conference call for NeuroOne Medical Technologies Corporation. Today's call will be conducted by the company's Chief Executive Officer, Dave Rosa, and Ron McCl ...

Hillman Solutions (NasdaqGM:HLMN) Q4 2025 Earnings call February 17, 2026 08:30 AM ET Company ParticipantsJon Michael Adinolfi - COOMichael Koehler - VP of Investor Relations and TreasurerRocky Kraft - CFOConference Call ParticipantsAndrew Carter - AnalystBrian McNamara - AnalystDavid Manthey - AnalystLee Jagoda - AnalystStephen Volkmann - AnalystOperatorGood morning, and welcome to the fourth quarter and full year 2025 results and 2026 guidance presentation for Hillman Solutions Corp. My name is Liz, and I ...

eToro Group (NasdaqGS:ETOR) Q4 2025 Earnings call February 17, 2026 08:30 AM ET Company ParticipantsBrett Knoblauch - Head of Digital Asset ResearchBrian Bedell - DirectorCraig Siegenthaler - Managing DirectorDaniel Amir - Head of Investor RelationsDevin Ryan - Director of Financial Technology ResearchJames Yaro - Managing Director of Equity ResearchJohn Todaro - Managing DirectorMeron Shani - CFORobin Holby - Equity Research AssociateYoni Assia - CEOConference Call ParticipantsAlex Kramm - Equity Research ...

Financial Data and Key Metrics Changes - The company reported product revenue of $2.9 million in Q1 fiscal 2026, down from $3.3 million in Q1 fiscal 2025, but up 5.5% from $2.7 million in Q4 fiscal 2025 [11][12] - The net loss for Q1 fiscal 2026 was $1.4 million, or a loss of $0.03 per share, compared to a net income of $1.8 million, or $0.06 per share, in the same quarter of the prior year [13] - Cash and cash equivalents as of December 31, 2025, were $3.6 million, down from $6.6 million as of September 30, 2025 [13][14] Business Line Data and Key Metrics Changes - The OneRF brain ablation system saw nearly half of all ablations performed since its launch in Q1 fiscal 2026, indicating strong market penetration [4] - The OneRF trigeminal nerve ablation system initiated a limited commercial launch, treating nine patients across three centers, all reporting pain relief [5][6] Market Data and Key Metrics Changes - The company is working towards receiving ISO 13485 certification to facilitate international commercialization of its technology [5] - The company attended the American Epilepsy Society meeting, showcasing its technology and receiving positive feedback from medical professionals [4] Company Strategy and Development Direction - The company is projecting fiscal year 2026 sales to be at least $10.5 million, representing a minimum 17% increase from fiscal year 2025 [3] - The company is in discussions with strategic partners for potential licensing of its trigeminal nerve ablation technology and is prepared to commercialize independently if necessary [7][22] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the continued positive momentum from fiscal year 2025 and the progress across various programs [3][16] - The company is focused on accelerating its drug delivery program, expecting devices for commercial use in investigational studies by Q3 fiscal 2026, six months ahead of schedule [7][8] Other Important Information - The company appointed Jason Mills to its board of directors, bringing valuable experience from his previous roles in strategy and investment banking [10] - The company had no debt outstanding as of December 30, 2025, indicating a strong financial position [14][15] Q&A Session Summary Question: Update on trigeminal nerve ablation cases and interest from Zimmer - The nine cases were performed at three centers, with all patients reporting pain relief. Discussions with strategic partners are ongoing, but the company is ready to commercialize independently if needed [21][22] Question: Expectations for operating expenses for the rest of the year - SG&A expenses are expected to remain flat, while R&D expenses may fluctuate based on project phases [25] Question: Clinical feedback from neurologists or surgical teams - Feedback indicates success in reducing or eliminating seizures, with procedures being performed at patients' bedsides, enhancing ease of use [33][35] Question: Sales and marketing responsibilities with Zimmer - Zimmer is responsible for all marketing and sales costs, while the company provides training and field support [37] Question: Revenue breakdown for Q1 - Most revenue was from restocking, following the initial stocking order in the previous fiscal year [38]

CEVA (NasdaqGS:CEVA) Q4 2025 Earnings call February 17, 2026 08:30 AM ET Company ParticipantsAlek Valero - Equity Research AssociateAmir Panush - CEORichard Kingston - VP of Investor RelationsRuben Roy - Managing DirectorYaniv Arieli - CFOConference Call ParticipantsKevin Cassidy - Senior Research AnalystSuji Desilva - Managing Director and Senior Research AnalystOperatorPlease note this event is being recorded. I would now like to turn the conference over to Richard Kingston, Vice President of Market Intel ...

Herc (NYSE:HRI) Q4 2025 Earnings call February 17, 2026 08:30 AM ET Company ParticipantsAaron Birnbaum - PresidentLarry Silber - CEOLeslie Hunziker - SVP of Investor Relations and CommunicationsMark Humphrey - SVP and CFONeil Tyler - DirectorRob Wertheimer - Founding Partner of Machinery and New Mobility ResearchTami Zakaria - Executive DirectorConference Call ParticipantsKen Newman - VP and Equity Research AnalystKyle Menghas - VP and Equity Research AnalystMig Dobre - Associate Director of Research and Se ...

Armada Hoffler Properties (NYSE:AHH) Q4 2025 Earnings call February 17, 2026 08:30 AM ET Company ParticipantsAndrew Berger - Equity Research AssociateChelsea Forrest - VP of Investor RelationsCraig Ramiro - EVP of Asset ManagementJon Petersen - Managing DirectorMatthew Barnes-Smith - CFOShawn Tibbetts - Chairman, President, and CEOViktor Fediv - Senior Equity Research AssociateOperatorThis call is being recorded on Tuesday, February 17, 2026. I would now like to turn the conference over to Chelsea Forrest, ...

Fluor (NYSE:FLR) Q4 2025 Earnings call February 17, 2026 08:30 AM ET Company ParticipantsJamie Cook - Managing DirectorJason Landkamer - VP of Investor RelationsJim Breuer - CEOJohn Regan - CFONatalia Alvarez Iragorri - SVPSteven Fisher - Managing DirectorConference Call ParticipantsAndrew Wittman - Senior Research AnalystMichael Dudas - Equity Research AnalystSangita Jain - Director and Equity Research AnalystOperatorGood morning, and welcome to Fluor's fourth quarter and Full Year 2025 Earnings Conference ...

eToro Group (NasdaqGS:ETOR) Q4 2025 Earnings call February 17, 2026 08:30 AM ET Company ParticipantsBrett Knoblauch - Head of Digital Asset ResearchBrian Bedell - DirectorCraig Siegenthaler - Managing DirectorDaniel Amir - Head of Investor RelationsDevin Ryan - Director of Financial Technology ResearchJames Yaro - VP of Equity ResearchJohn Todaro - Managing DirectorMeron Shani - CFORobin Holby - Equity Research AssociateYoni Assia - CEOConference Call ParticipantsAlex Kramm - Equity Research AnalystDan Dole ...

Orion S.A. (NYSE:OEC) Q4 2025 Earnings call February 17, 2026 08:30 AM ET Company ParticipantsChris Kapsch - VP of Investor RelationsCorning Painter - CEOJohn Roberts - Managing DirectorJon Puckett - CFOJon Tanwanteng - Managing DirectorConference Call ParticipantsDan Rizzo - SVP and Equity AnalystJeff Zekauskas - Managing Director and Senior Equity Research AnalystJosh Spector - Equity Research AnalystOperatorGreetings. Welcome to the Orion S.A. fourth quarter 2025 earnings conference call. At this time, a ...